

## **Wet Age-Related Macular Degeneration**

1. A Phase 1 Ascending and Parallel Group Trial to Establish the Safety, Tolerability and Pharmacokinetics Profile of Volociximab (Alpha 5 Beta 1 Integrin Antagonist) in Subjects With Neovascular Age-Related Macular Degeneration:  
<http://clinicaltrials.gov/ct2/show/NCT00782093>
2. Safety and Efficacy Study of Intravitreal Microplasm in Subjects With AMD With Focal Vitreomacular Adhesion (MIVI-5):  
<http://clinicaltrials.gov/ct2/show/NCT00913744>
3. A Safety and Efficacy Study of E10030 (Anti-PDGF Pegylated Aptamer) Plus Lucentis for Neovascular Age-Related Macular Degeneration:  
<http://clinicaltrials.gov/ct2/show/NCT01089517>

## **Dry Age-Related Macular Degeneration**

1. Epidemiologic Study of Patients With Geographic Atrophy Due to Age-Related Macular Degeneration

## **Wet or Dry Age-Related Macular Degeneration**

1. Intravitreal LFG316 in Patients With Age-related Macular Degeneration:  
<http://clinicaltrials.gov/ct2/show/NCT01255462>

## **Ischemic Central Retinal Vein Occlusion**

1. Study of 2.0 mg Ranibizumab in Subjects With Ischemic Central Retinal Vein Occlusion (RAVE 2):  
<http://clinicaltrials.gov/ct2/show/NCT01225146>

## **Retinal Vein Occlusion**

1. A Study Evaluating Dosing Regimens for Treatment With Intravitreal Ranibizumab Injections in Subjects With Macular Edema Following Retinal Vein Occlusion (SHORE):

<http://clinicaltrials.gov/ct2/show/NCT01277302>

2. Safety and Efficacy of AGN208397 in the Treatment of Macular Edema Associated With Retinal Vein Occlusion (RVO):

<http://clinicaltrials.gov/ct2/show/NCT01027650>

## **Uveitis**

1. A Study of the Efficacy and Safety of Adalimumab in Subjects With Inactive Uveitis:

<http://clinicaltrials.gov/ct2/show/NCT01124838>

2. Efficacy and Safety of Adalimumab in Subjects With Active Uveitis:

<http://clinicaltrials.gov/ct2/show/NCT01138657>

3. Safety and Efficacy of AIN457 in Noninfectious Uveitis:

<http://clinicaltrials.gov/ct2/show/NCT00685399>